Severe sepsis and Toll-like receptors

被引:46
作者
Gao, Hongmei [1 ]
Leaver, Susannah K. [1 ]
Burke-Gaffney, Anne [1 ]
Finney, Simon J. [1 ]
机构
[1] Natl Heart & Lung Inst, Unit Crit Care Med, London SW3 6LY, England
关键词
sepsis; Toll-like receptors; gram-positive bacterial infections; gram-negative bacterial infections; viral infections; fungal infections;
D O I
10.1007/s00281-007-0101-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Severe sepsis dominates the mortality of non-cardiac intensive care units. The ingenious Toll-like receptor (TLR) system can recognise many infectious organisms through relatively few receptors to trigger pro-inflammatory and anti-inflammatory cytokine release. Further complexity arises from positive and negative signalling feedback loops. Severe sepsis may be a consequence of an inappropriately excessive response or inadequate endogenous negative feedback. Therapies targeting these pathways are currently being evaluated. Alternatively, in clinical scenarios such as compensatory anti-inflammatory response syndrome, chronic viral sepsis or inadequate vaccine function, TLR signalling may be inadequate. TLR agonists may augment the innate response and are being investigated.
引用
收藏
页码:29 / 40
页数:12
相关论文
共 120 条
[1]
Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[2]
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[3]
Treatment of viral and neoplastic diseases with double-stranded RNA derivatives and other new agents [J].
Ambrus, Julian L., Sr. ;
Chadha, Kailash C. ;
Islam, Anwarul ;
Akhter, Selina ;
Ambrus, Julian L., Jr. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2006, 231 (08) :1283-1286
[4]
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[5]
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis [J].
Arevalo, Iracema ;
Tulliano, Gianfranco ;
Quispe, Ana ;
Spaeth, Gerald ;
Matlashewski, Greg ;
Llanos-Cuentas, Alejandro ;
Pollack, Henry .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (12) :1549-1554
[6]
Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis [J].
Armstrong, L ;
Medford, ARL ;
Hunter, KJ ;
Uppington, KM ;
Millar, AB .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (02) :312-319
[7]
Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA [J].
Ashkar, AA ;
Yao, XD ;
Gill, N ;
Sajic, D ;
Patrick, AJ ;
Rosenthal, KL ;
Rosenthal, L .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (10) :1841-1849
[8]
Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients? [J].
Azoulay, É ;
Delclaux, C .
INTENSIVE CARE MEDICINE, 2004, 30 (01) :10-17
[9]
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents [J].
Baldridge, JR ;
McGowan, P ;
Evans, JT ;
Cluff, C ;
Mossman, S ;
Johnson, D ;
Persing, D .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1129-1138
[10]
Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients [J].
Ben-Ali, M ;
Barbouche, MR ;
Bousnina, S ;
Chabbou, A ;
Dellagi, K .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (03) :625-626